Streptococcus pneumoniae can induce local and systemic diseases such as meningitis, otitis media, and pneumonia. One third of these meningitis cases can be associated with irreversible sensorineural hearing loss whose mechanisms likely involves the exotoxin pneumolysin (PLY) that irreversibly damages cochlear hair cells (HCs). In the respiratory system and in neuron it has been demonstrated that zinc deficiency increases severity and mortality of such infections in animal models and in children. Moreover, zinc supplementation can decrease the severity of pneumococcal respiratory infections. The aim of our study was to assess the potential protective effect of zinc against PLY toxicity on HCs in culture. Our results showed that in the presence of zinc at concentration as low as 1 µM, the toxicity of PLY was largely reduced by about 50% for both inner and outer HCs. At 300 µM of zinc, protection significantly increased with 62 and 55.2% for IHCs and OHCs, respectively. Our results suggest that the protective effect of zinc is likely due to an inhibition of the toxin incorporation and aggregation into the plasma membrane, thus preventing calcium influx through the toxin pores. Our findings raise the possibility that treatments with zinc may help to prevent debilitating otological sequelae from pneumococcal infection.

Keywords:
Pneumolysin, Hair cells, Zinc, Meningitis, Toxicity
1.
Alouf JE: Cholesterol-binding cytolytic protein toxins. Int J Med Microbiol 2000;290:351–356.
2.
Beurg M, Hafidi A, Skinner L, Cowan G, Hondarrague Y, Mitchell TJ, Dulon D: The mechanism of pneumolysin-induced cochlear hair cell death in the rat. J Physiol 2005;568:211–227.
3.
Bodmer D, Brors D, Pak K, Bodmer M, Ryan AF: Gentamicin-induced hair cell death is not dependent on the apoptosis receptor Fas. Laryngoscope 2003;113:452–455.
4.
Braun JS, Sublett JE, Freyer D, Mitchell TJ, Cleveland JL, Tuomanen EI, Weber JR: Pneumococcal pneumolysin and H2O2 mediate brain cell apoptosis during meningitis. J Clin Invest 2002;109:19–27.
5.
Comis SD, Osborne MP, Stephen J, Tarlow MJ, Hayward TL, Mitchell TJ, Andrew PW, Boulnois GJ: Cytotoxic effects on hair cells of guinea pig cochlea produced by pneumolysin, the thiol-activated toxin of Streptococcus pneumoniae. Acta Otolaryngol 1993;113:152–159.
6.
Dodge PR, Davis H, Feigin RD, Holmes SJ, Kaplan SL, Jubelirer DP, Stechenberg BW, Hirsh SK: Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med 1984;311:869–874.
7.
Fortnum HM: Hearing impairment after bacterial meningitis: a review. Arch Dis Child 1992;67:1128–1133.
8.
Fraker PJ: Roles for cell death in zinc deficiency. J Nutr 2005;135:359–362.
9.
Gilbert RJ, Jimenez JL, Chen S, Tickle IJ, Rossjohn J, Parker M, Andrew PW, Saibil HR: Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae. Cell 1999;97:647–655.
10.
Kesser BW, Hashisaki GT, Spindel JH, Ruth RA, Scheld WM: Time course of hearing loss in an animal model of pneumococcal meningitis. Otolaryngol Head Neck Surg 1999;120:628–637.
11.
Kopke RD, Liu W, Gabaizadeh R, Jacono A, Feghali J, Spray D, Garcia P, Steinman H, Malgrange B, Ruben RJ, Rybak L, Van de Water TR: Use of organotypic cultures of Corti’s organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 1997;18:559–571.
12.
Korchev YE, Bashford CL, Pasternak CA: Differential sensitivity of pneumolysin-induced channels to gating by divalent cations. J Membr Biol 1992;127:195–203.
13.
Korchev YE, Bashford CL, Pederzolli C, Pasternak CA, Morgan PJ, Andrew PW, Mitchell TJ: A conserved tryptophan in pneumolysin is a determinant of the characteristics of channels formed by pneumolysin in cells and planar lipid bilayers. Biochem J 1998;329:571–577.
14.
Kumar S, Awasthi S, Jain A, Srivastava RC: Blood zinc levels in children hospitalized with severe pneumonia: a case control study. Indian Pediatr 2004;41:486–491.
15.
Low W, Dazert S, Baird A, Ryan AF: Basic fibroblast growth factor (FGF-2) protects rat cochlear hair cells in organotypical culture from aminoglycoside injury. J Cell Physiol 1996;167:443–450.
16.
Mahalanabis D, Lahiri M, Paul D, Gupta S, Gupta A, Wahed MA, Khaled MA: Randomized, double-blind, placebo-controlled clinical trial of the efficacy of treatment with zinc or vitamin A in infants and young children with severe acute lower respiratory infection. Am J Clin Nutr 2004;79:430–436.
17.
Milton AG, Zalewski PD, Ratnaike RN: Zinc protects against arsenic-induced apoptosis in a neuronal cell line, measured by DEVD-caspase activity. Biometals 2004;17:707–713.
18.
Naganska E, Matyja E: Apoptotic neuronal changes enhanced by zinc chelator – TPEN in organotypic rat hippocampal cultures exposed to anoxia. Folia Neuropathol 2006;44:125–132.
19.
Saunders FK, Mitchell TJ, Walker JA, Andrew PW, Boulnois GJ: Pneumolysin, the thiol-activated toxin of Streptococcus pneumoniae, does not require a thiol group for in vitro activity. Infect Immun 1989;57:2547–2552.
20.
Skinner LJ, Beurg M, Mitchell TJ, Darrouzet V, Aran JM, Dulon D: Intracochlear perfusion of pneumolysin, a pneumococcal protein, rapidly abolishes auditory potentials in the guinea pig cochlea. Acta Otolaryngol 2004;124:1000–1007.
21.
Sobkowicz HM, Loftus JM, Slapnick SM: Tissue culture of the organ of Corti. Acta Otolaryngol Suppl 1993;502:3–36.
22.
Spreer A, Kerstan H, Bottcher T, Gerber J, Siemer A, Zysk G, Mitchell TJ, Eiffert H, Nau R: Reduced release of pneumolysin by Streptococcus pneumonia e in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother 2003;47:2649–2654.
23.
Strand TA, Briles DE, Gjessing HK, Maage A, Bhan MK, Sommerfelt H: Pneumococcal pulmonary infection, septicaemia and survival in young zinc-depleted mice. Br J Nutr 2001;86:301–306.
24.
Strand TA, Hollingshead SK, Julshamn K, Briles DE, Blomberg B, Sommerfelt H: Effects of zinc deficiency and pneumococcal surface protein a immunization on zinc status and the risk of severe infection in mice. Infect Immun 2003;71:2009–2013.
25.
Stringaris AK, Geisenhainer J, Bergmann F, Balshusemann C, Lee U, Zysk G, Mitchell TJ, Keller BU, Kuhnt U, Gerber J, Spreer A, Bahr M, Michel U, Nau R: Neurotoxicity of pneumolysin, a major pneumococcal virulence factor, involves calcium influx and depends on activation of p38 mitogen-activated protein kinase. Neurobiol Dis 2002;11:355–368.
26.
Thorne PR, Carlisle L, Zajic G, Schacht J, Altschuler RA: Differences in the distribution of F-actin in outer hair cells along the organ of Corti. Hear Res 1987;30:253–265.
27.
Tilley SJ, Orlova EV, Gilbert RJ, Andrew PW, Saibil HR: Structural basis of pore formation by the bacterial toxin pneumolysin. Cell 2005;121:247–256.
28.
Truong-Tran AQ, Grosser D, Ruffin RE, Murgia C, Zalewski PD: Apoptosis in the normal and inflamed airway epithelium: role of zinc in epithelial protection and procaspase-3 regulation. Biochem Pharmacol 2003;66:1459–1468.
29.
Winter AJ, Comis SD, Osborne MP, Tarlow MJ, Stephen J, Andrew PW, Hill J, Mitchell TJ: A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs. Infect Immun 1997;65:4411–4418.
© 2008 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.